Companies · Listed company · 🇮🇳

Sun Pharma Advanced Research Company Limited

SPARC · NSE · ₹191 a share (close of 05 Oct 2026)

Available company data, source links and archived checks for Sun Pharma Advanced Research Company Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.

Revenue rose 314.1%; Net loss was ₹20.78 crore.

Quarter ended 2026-06-30 · consolidated · Company filing

Recorded quarterly figures
QuarterRevenue / incomeYoY ProfitYoYNet marginSource
Jun 2026Revenue: ₹40 cr+314.1%Net profit: ₹-21 cr—-52.1%Company filing source
Mar 2026Revenue: ₹1,853 cr+6715.8%Net profit: ₹1,761 cr—95.0%Company filing source
Dec 2025Revenue: ₹8 cr—Net profit: ₹-80 cr—-951.7%Company filing source
Sep 2025Revenue: ₹8 cr—Net profit: ₹-76 cr—-965.0%Company filing source
Jun 2025Revenue: ₹10 cr-42.7%Net profit: ₹-52 cr—-538.1%Company filing source
Mar 2025Revenue: ₹27 cr—Net profit: ₹-60 cr—-219.8%Company filing source

YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.

Who holds it — from the filings
Shanghvi Finance Private Limited 42.3%Dilip.S.Shanghvi 19.1%Sun Pharmaceutical Industries Key Employees Benefit Trust 3.2%Lakshdeep Investments & Finance (P) Ltd. 1.9%Aditya Medisales Limited 1.5%register as filed 2026-06-30
Filing timeline — what the company told the exchange

Follow this company without reading every document yourself.

Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.

Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment advice · cancel any time
Or just the free morning: three facts checked against filings, every trading day, in your inbox.

Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances